Clinical trial NCT04123600: Origin Stem and Logical Cup Post Market Clinical Follow-up
Official title: Origin Stem and Logical Cup Post Market Clinical Follow-up
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hip Disease
Keywords: Hip Replacement
Lead sponsor: Signature Orthopaedics
Sponsor class: INDUSTRY
Collaborators: name: The Cleveland Clinic
First posted: 2019-10-11
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of the Cleveland Clinic

Brief summary: The aim of the study is to monitor the performance of the Signature Orthopaedics Origin Stem and Logical Acetabular Cup as part of post-market vigilance and continuous improvement efforts.

Detailed description: The objective of this PMCF study is to collect data confirming safety, performance and clinical benefits of the Origin Stem and Logical Cup when used for primary total hip arthroplasty at 2 years follow-up. This prospective follow-up series is necessary to obtain data specific to the Origin Stem and Logical Cup considering their relatively recent launch to the market.

The study includes pre-operative, operative, discharge, 1 year post-operative and 2 year post-operative evaluations, where data concerning the performance and safety of the device are gathered. In particular, the revision rate of the components will be monitored as the primary objective, along with pre- and post-operative measurement of the Oxford Hip Score (OHS) patient-reported outcome measure (PROM) to quantify patient satisfaction, and radiographic analysis to monitor bony response to the implant and qualify the effectiveness of the cementless fixation.

Eligibility criteria: Inclusion Criteria:

* patient requires unilateral primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, avascular necrosis, dysplasia/DDH)
* patient must be a candidate for use of the products studied, as determined jointly by the surgeon and patient
* male and non-pregnant female patients aged 18-75
* patients who understand the conditions of the clinical evaluation and are willing to participate for the length of the prescribed follow-up

Exclusion Criteria:

* patient has active infection or sepsis (treated or untreated)
* patient has any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery.
* patient is female of child-bearing age and not taking contraceptive precautions
* patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia)
* patient has inflammatory joint disease (e.g. rheumatoid arthritis)
* patient has known moderate to severe renal deficiency
* patient has a known or suspected metal sensitivity
* patient is immuno-suppressed with diseases such as AIDS or is receiving high dose of corticosteroids
* patient has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the clinical evaluation including mental illness, mental retardation or drug abuse
* patient is severely overweight with a BMI\>40.

Primary outcomes:
measure: Stem and Cup Survival Rate
timeFrame: up to 2 years
Secondary outcomes:
measure: Oxford Hip Score (OHS)
timeFrame: up to 2 years
measure: Radiographic Analysis
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Atul Kamath, MD
role: PRINCIPAL_INVESTIGATOR
References: